3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Classical hematology
1
Conditions
Venous Thromboembolism
1
Thrombosis
1
Thrombophilia
1
Thromboembolism
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Pulmonary Embolism
1
Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery
1
Multiple Myeloma
1
Lymphoma
1
Leukemia
1
Hematologic Neoplasms
1
Esophageal Neoplasms
1
Digestive System Diseases
1
Interventions
Dalteparin
10
apixaban
9
Tinzaparin
4
Enoxaparin
4
Heparin, Low-Molecular-Weight
3
edoxaban
2
abelacimab
2
Rivaroxaban
2
MAA868
2
Dabigatran
2
perflutren
1
isoquercitrin
1
enoxaparin sodium
1
bemiparin
1
Warfarin
1
Sulfur Hexafluoride
1
Rosuvastatin Calcium
1
Hospitals
1
Fondaparinux
1
Fluorodeoxyglucose F18
1
Educational Status
1
Deoxyribonucleases
1
Acetylcysteine
1
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Pulmonary Embolism
×
enoxaparin sodium
×
Clear all
NCT07270263
2025-12-26
HEM-DOAC
Medical University of Gdansk
Phase NA
Recruiting
100 enrolled